The clinical need for treatment of TP53 double-hit MM patients is imminent, but unfortunately there are no proven drug approaches that target this lesion, as efforts to pharmacologically re-activate mutant p53 have not yet led to specific therapies24. The gene discussed is TP53; the disease is Miyoshi myopathy.